tirzepatide oklahoma Enhanced FDA shakes up weight loss

previously, this vaccine was available under emergency use authorization (EUA) for active immunization to prevent COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 12 years of age Indicated for (1) active immunization to prevent COVID-19 caused by SARS-CoV-2 in adults 65 years of age, and (2) for individuals 12 through 64 years of age who have at least one underlying condition that puts them at high risk for severe outcomes from COVID-19 (e.g., asthma, cancer, diabetes, obesity, smoking) Injectable suspension: 0.5 mL in a prefilled syringe Recommended dosage is a single 0.5 mL dose administered intramuscularly (IM) by an HCP

No headaches, no vomiting, just slight constipation

Mild pain and swelling

It requires immediate refrigeration (2C to 8C) upon arrival